Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Allopurinol on Blood Lipids and Drug Adherence in Dialysis Patients
IRCT20260425069150N1Phase 3Recruiting
- Sponsor
- Hamadan University of Medical Sciences
- Start
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of allopurinol in end-stage kidney disease (ESKD) and hyperuricemia, sponsored by Hamadan University of Medical Sciences. Primary endpoints: Change in blood lipid profile and Medication adherence. Started Sep 2025; status: recruiting.
02
Drugs
allopurinol
03
Conditions
end-stage kidney disease (ESKD)hyperuricemia
Beyond the preview
Go deeper on IRCT20260425069150N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20260425069150N1.